- Diagnostics technology company Oncocyte (NASDAQ:OCX) entered into a securities purchase agreement with new and existing investors, including Bio-Rad Laboratories, one of the company’s strategic partners.
- The gross proceeds are expected to be ~$10.2M.
- Net proceeds to be deployed for working capital and